Coherus Biosciences
Presence
Coherus Biosciences is one of the...
Coherus Biosciences is a company listed under the stock ticker CHRS (US).
Acquisition, funding and merger involving Coherus Biosciences.
- Coherus Biosciences has announced the acquisition of Surface Oncology (posted on September 11 2023).
- Coherus Biosciences has announced the acquisition of Surface Oncology (posted on June 19 2023).
- Coherus Biosciences has just announced a $50 Million fundraising (posted on May 19 2023).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at Coherus Biosciences
- Dennis Lanfear, President, Chairman and Chief Executive Officer
- Ali Satvat, Director
- Jill O'Donnell-Tormey, Director
Popular executive movements at Coherus Biosciences
- Mcdavid Stilwell, Chief Financial Officer, will leave the company on Dec. 31, 2023 (posted on December 8 2023).
- Michael Ryan has joined the company as Director (posted on July 21 2023).
Create your alert
to follow the executive moves at Coherus Biosciences.
Biotechnology
Coherus Biosciences has 2,276 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Coherus Biosciences
- FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity | Coherus BioSciences, Inc.
- Coherus BioSciences Announces New Employment Inducement Grants | Coherus BioSciences, Inc.
- Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022 | Coherus BioSciences, Inc.
- Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma | Coherus BioSciences, Inc.
- Coherus BioSciences Announces New Employment Inducement Grants | Coherus BioSciences, Inc.
- Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors | Coherus BioSciences, Inc.
- Coherus BioSciences Management to Present at Upcoming Investor Conferences | Coherus BioSciences, Inc.
- Coherus BioSciences Reports First Quarter 2022 Results | Coherus BioSciences, Inc.
- Coherus BioSciences Appoints Charlie Newton to Board of Directors | Coherus BioSciences, Inc.
- Coherus BioSciences Announces New Employment Inducement Grants | Coherus BioSciences, Inc.
- View more press releases Close
Social media about Coherus Biosciences
- Coherus Biosciences on Wikipedia, Google News & Yahoo Finance
- Coherus Biosciences on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Lee Newcomer 
Call Coherus Biosciences at +1 805...
